Notably, auranofin treatment did not provoke the strong downregulation of TXNL1 typically seen previously in proteomics studies using cancer cell line models [40,45,46], and neither auranofin nor TRi-1 seemed to have triggered clear upregulation of NRF2 targets in this data set. Here, TXNL1 is linked to cancer.